Stan Musial

Stan Musial has extensive work experience in the biopharmaceutical industry. Stan has held various leadership positions in different companies, showcasing their expertise in finance and business operations.

Stan began their career as the Chief Financial Officer (CFO) at Strategic Diagnostics in 2002 and held this role until 2004. Following this, they served as the CFO at Prism Pharmaceuticals, where they successfully managed the company's investment banking process and played a key role in its acquisition.

In 2011, Musial became an independent consultant at SJM Consulting, where they provided their expertise as a Certified Public Accountant (CPA) and a Master of Business Administration (MBA) until 2013. During this time, their responsibilities included offering financial advice and support to various clients.

Musial then joined Egalet Corporation as the CFO, Executive Vice President, and Secretary in 2013. Stan played a crucial role in the company's initial public offering and contributed to the development of tamper-resistant opioids using innovative drug delivery technologies. In 2018, they transitioned to ERYDEL SPA as the CFO, overseeing the development of drugs delivered through red blood cells for the treatment of Ataxia Telangiectasia.

In 2019, Musial joined Xenikos B.V. as the Chief Business Officer and CFO, where they focused on developing immunotherapy medicines to help patients suffering from immune diseases. Stan remained in this role until 2021, when they joined Aruvant Sciences as the CFO. During their time at Aruvant, they played a crucial role in the development and commercialization of gene therapy products for rare diseases, particularly sickle cell disease.

Most recently, Musial took on the role of CFO at Promontory Therapeutics, a clinical-stage pharmaceutical company specializing in small molecule immunotherapy. In this position, they are responsible for overseeing the company's financial operations and supporting the development of innovative cancer treatments.

Overall, Stan Musial's work experience demonstrates their versatility and expertise in the biopharmaceutical industry, with a particular focus on finance, business operations, and the development of transformative therapies for rare diseases.

Stan Musial attended Penn State University from 1979 to 1983, where they obtained a Bachelor of Science degree in Accounting. Stan then pursued a Master of Business Administration degree in Finance at Temple University from 1983 to 1988. In 2017, Musial attended the Northwestern University - Kellogg School of Management's Executive Education Program, focusing on Corporate Board Governance.